Fig. 5

Lycorine binds to EGFR, inhibits EGF-activated EGFR phosphorylation and exhibits an EGFR-dependent manner to suppress GBM cells proliferation. a Biacore assay to reveal the SPR analysis of the binding between Lycorine and EGFR (696–1022) domain. The purified EGFR (696–1022) protein was immobilized on an activated CM5 sensor chip. Lycorine was then flowed across the chip. b U251 cells were pretreated with or without 25 μM Lycorine for 1 h then followed by 100 ng/mL EGF treatment for 0, 15, 30, 45 and 60 min (Lycorine was maintained during the EGF-treated time course), and EGF-dependent EGFR phosphorylation was measured by western blotting. c Statistical result of Fig. 5b. d After successful construction of stable U251 shEGFR cells, the knockdown efficiency of EGFR protein was detected by Western blotting in Parental (normal U251 cells), shControl and shEGFR stably constructed U251 cells, respectively. e Statistical result of Fig. 5d. f Parental (normal U251 cells), shControl and shEGFR stably constructed U251 cells were seeded in 96 well plates for indicated days and cell viability was assessed by SRB assay.g Statistic result of cell proliferation when EGFR was interfered by shRNA. Parental (normal U251 cells), shControl and shEGFR stably constructed U251 cells with shRNA were treated with indicated concentrations of Lycorine (0 μM, 10 μM and 20 μM) for 48 h and cell viability was detected by SRB assay. All data are represented as mean ± S.D. from triplicate wells. *, p < 0.05, **, p < 0.01, as compared to control